Last Price
2.28
Today's Change
-0.50 (17.98%)
Day's Change
2.28 - 2.68
Trading Volume
4,387,815
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D. Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Full Time Employees: 66 66
IPO Date: 2021-07-30 2021-07-30
CIK: 0001790340 0001790340
ISIN: US45254E1073 US45254E1073
CUSIP: 45254E107 45254E107
Beta: -0.61 -0.61
Last Dividend: 0.00 0.00
Dcf Diff: 0.35 0.35
Dcf: 1.93 1.93
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.